<![CDATA[FDA Approves Atezolizumab/Chemo for Stage III dMMR/MSI-H Colon Cancer]]>
NDA FilingapprovedAtezolizumabChemotherapyPositive
AI Analysis
Summary
The FDA approved adjuvant atezolizumab combined with chemotherapy for patients with resected stage III dMMR or MSI-H colon cancer, based on positive Phase 3 ATOMIC trial results.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
FDA approval for adjuvant atezolizumab with chemotherapy for resected stage III dMMR or MSI-H colon cancer
Importance:8/10
Sentiment:
0.90
FDA ApprovalColon CancerImmunotherapydMMRMSI-HAdjuvant Therapy
Related Companies
Read the original article
Published by Cancer Network on October 8, 2026 6:06 PM